From left: George Mantas (AquaBioTech Group), Kjetil Haga (Bluefront Equity), Jan Sverre Røsstad (Bluefront), Shane Hunter (AquaBioTech), Alf-Helge Aarskog (Bluefront), Robert Davies (AquaBioTech). Photo: AquaBioTech Group.
From left: George Mantas (AquaBioTech Group), Kjetil Haga (Bluefront Equity), Jan Sverre Røsstad (Bluefront), Shane Hunter (AquaBioTech), Alf-Helge Aarskog (Bluefront), Robert Davies (AquaBioTech). Photo: AquaBioTech Group.

Seafood investor to take stake in AquaBioTech Group

Norwegian seafood investor Bluefront Equity has agreed to acquire a significant stake in Malta-based AquaBioTech Group.

Published

The planned investment will be made through a combination of purchase of shares and new capital, AquaBioTech Group said in a press release, and will enable to company to continue rapidly developing international expansion plans.

Three divisions

AquaBioTech Group comprises three divisions – an aquaculture, fisheries and marine environment consulting, advisory and training company; a contract research organisation that is one of the largest licensed aquatic CRO facilities in the European Union; and an engineering and development company focused on the turnkey supply of recirculating aquaculture systems (RAS) for commercial and research purposes.

The company was established in 1996 and has more than 100 staff recruited from over 25 countries and clients and projects in more than 55 countries.

Bluefront Equity is an Oslo based pure-play seafood investment fund created by Kjetil Haga and Simen Landmark in 2020. The core team consists of former Mowi chief executive Alf Helge Aarskog, Nova Sea chairwoman Aino Olaisen and former BioMar executive Jan Sverre Røsstad in addition to Haga and Landmark.